The legality of ‘reverse payments’ in the EU

No items found.
​
01 July 2013
Tags
Litigation
Life
Table of contents
  • Toc Heading
  • Toc Heading

In a guest post for the Spicy IP blog, partner Gary Moss discusses the practice of ‘reverse payments’, where a pharmaceutical company, which owns a patent, pays off a generic competitor to not enter the market.

It follows fines totalling €146 Million given by the European Commission to Lundbeck and four other generic companies (Merck KGaA/Generics UK, Arrow, Alphapharma, and Ranbaxy).

Related articles

See all articles

EIP appoints Catherine Howell as Partner, marking the firm’s first home‑grown litigation partner
05 March 2026
EIP is pleased to announce the promotion of Catherine Howell to Partner, marking a significant milestone as she becomes the firm’s first home‑grown litigation partner. Catherine joined EIP as a Trainee Solicitor in 2015 and has progressed through every stage of the firm’s litigation practice, most recently serving as Managing Associate.
​
EIP welcomes Anders Hansson as Partner to further strengthen our digital practice
19 January 2026
EIP is pleased to welcome Anders Hansson as Partner, bringing nearly 20 years of experience in AI, robotics, digital technologies, and European patent strategy. His industry and private‑practice background further strengthens our digital and high‑tech capabilities across Europe.
​
EIP Recognised in The Times Best Law Firms 2026
03 December 2025
EIP is proud to be featured in The Times Best Law Firms 2026, a prestigious list based on peer recommendations across the legal industry. This recognition highlights EIP’s commitment to technical excellence, client-focused service, and innovative IP strategies. From high-value patent litigation to strategic portfolio management, EIP continues to deliver results that matter for clients in technology, life sciences, and engineering. This accolade reinforces our position as a trusted leader in intellectual property law.
​